Gastrointestinal stromal tumors: prospects for drug therapy of metastatic or inoperable forms

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal mesenchymal tumors. Treatment of metastatic GISTs is determined by the molecular subtype of the tumor. The use of tyrosine kinase inhibitors, in particular imatinib, which is used as the standard first line treatment for metastatic tumors has been a revolution in the treatment of GIST. Despite the high efficacy of the drug, most patients develop resistance to the treatment, usually after 2–3 years. In the second and third lines of treatment, such drugs as sunitinib and regorafenib are used, respectively. In 2020, the FDA approved ripretinib as a fourth-line treatment, and in the presence of a mutation in the 18th exon of the PDGFRA gene; avapritinib began to be used from the same year. This review article describes standards and therapeutic approaches for the treatment of metastatic GISTs.

全文:

受限制的访问

作者简介

Mikhail Abramov

N.N. Blokhin National Medical Research Center of Oncology

编辑信件的主要联系方式.
Email: abramovm67@mail.ru
ORCID iD: 0000-0003-4754-2352

Cand. Sci. (Med.), Senior Researcher at the Oncological Department of Medicinal Methods of Treatment (Chemotherapeutic) № 4

俄罗斯联邦, Moscow

T. Tikhomirova

N.N. Blokhin National Medical Research Center of Oncology

Email: abramovm67@mail.ru
ORCID iD: 0000-0002-7313-4013
俄罗斯联邦, Moscow

O. Ryabishina

N.N. Blokhin National Medical Research Center of Oncology

Email: abramovm67@mail.ru
ORCID iD: 0000-0002-7871-0358
俄罗斯联邦, Moscow

A. Rumyantsev

N.N. Blokhin National Medical Research Center of Oncology

Email: abramovm67@mail.ru
ORCID iD: 0000-0003-4443-9974
俄罗斯联邦, Moscow

A. Tyulyandina

N.N. Blokhin National Medical Research Center of Oncology; Sechenov University

Email: abramovm67@mail.ru
ORCID iD: 0000-0002-6104-7473

Department of Oncology, N.V. Sklifosovsky Institute of Clinical Medicine

俄罗斯联邦, Moscow; Moscow

参考

  1. Liao W., Xu H., Hutton D., et al. Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors. Front Oncol. 2021;11:692005. doi: 10.3389/fonc.2021.692005.
  2. Miettinen M., Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438(1):1–12. doi: 10.1007/s004280000338.
  3. Judson I., Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol. 2007;18(Suppl 10):x20–4. doi: 10.1093/annonc/mdm410.
  4. Corless C.L., Barnett C.M., Heinrich M.C. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11(12):865–78. doi: 10.1038/nrc3143.
  5. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357–64. doi: 10.1200/JCO.2005.14.068.
  6. Andersson J., Sihto H., Meis-Kindblom J.M., et al. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol. 2005;29(9):1170–76. doi: 10.1097/01.pas.0000159775.77912.15.
  7. Daniels M., Lurkin I., Pauli R., et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 2011;312(1):43–54. doi: 10.1016/j.canlet.2011.07.029.
  8. Patrikidou A., Domont J., Chabaud S., et al. French Sarcoma Group. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer. 2016;52:173–80. doi: 10.1016/j.ejca.2015.10.069.
  9. Miettinen M., Wang Z.F., Sarlomo-Rikala M., et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011;35(11):1712–21. doi: 10.1097/PAS.0b013e3182260752.
  10. Nishida T., Blay J.Y., Hirota S., et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8.
  11. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80. doi: 10.1056/NEJMoa020461.
  12. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–25. doi: 10.1200/JCO.2007.13.4403.
  13. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38. doi: 10.1016/S0140-6736(06)69446-4.
  14. Shirao K., Nishida T., Doi T., et al. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs. 2010;28(6):86–75. doi: 10.1007/s10637-009-9306-9.
  15. George S., Blay J.Y., Casali P.G., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45(11):1959–68. doi: 10.1016/j.ejca.2009.02.011.
  16. Demetri G.D., Reichardt P., Kang Y.K., et al. GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. doi: 10.1016/S0140-6736(12)61857-1.
  17. Son M.K., Ryu M.H., Park J.O., et al. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. Cancer Res Treat. 2017;49(2):350–57. doi: 10.4143/crt.2016.067.
  18. Kang Y.K., Ryu M.H., Yoo C., et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175–82. doi: 10.1016/S1470-2045(13)70453-4.
  19. Blay J.Y., Serrano C., Heinrich M.C., et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923–34. doi: 10.1016/S1470-2045(20)30168-6.
  20. Schoffski P., Mir O., Kasper B., et al. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’. Eur J Cancer. 2020;134:62–74. doi: 10.1016/j.ejca.2020.04.021.
  21. von Mehren M., Kane J.M., Agulnik M., et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(7):815–33. doi: 10.6004/jnccn.2022.0035.
  22. Casali P.G., Abecassis N., Aro H.T., et al. ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv68-iv78. doi: 10.1093/annonc/mdy095. Erratum in: Ann Oncol. 2018;29(Suppl 4):iv267.
  23. Jones R.L., Serrano C., von Mehren M., et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021;145:132–42. doi: 10.1016/j.ejca.2020.12.008.
  24. Kang Y.K., George S., Jones R.L., et al. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021;39(28):3128–39. doi: 10.1200/JCO.21.00217.
  25. Kelany M., Barth T.F., Salem D., Shakweer M.M. Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas. Pathol Oncol Res. 2021;27:1609804. doi: 10.3389/pore.2021.1609804.
  26. D’Angelo S.P., Mahoney M.R., Van Tine B.A., et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–26. doi: 10.1016/S1470-2045(18)30006-8.
  27. Toulmonde M., Penel N., Adam J., et al. Combination of pembrolizumab andmetronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial. 2017 ASCO Annual Meeting. J Clin Oncol. 2017;35:(suppl); abstr 11053.
  28. Kurokawa Y., Honma Y., Sawaki A., et al. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2022;33(9):959–67. doi: 10.1016/j.annonc.2022.05.518.
  29. Chi P., Qin LX., Nguyen B., et al. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. J Clin Oncol. 2022;40(9):997–1008. doi: 10.1200/JCO.21.02029.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##